Harold Bernstein Sells 412 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 412 shares of Maze Therapeutics stock in a transaction on Monday, January 5th. The stock was sold at an average price of $40.00, for a total transaction of $16,480.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Harold Bernstein also recently made the following trade(s):

• On Friday, January 2nd, Harold Bernstein sold 4,432 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.43, for a total transaction of $179,185.76.
• On Monday, December 29th, Harold Bernstein sold 45,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.56, for a total transaction of $1,825,200.00.

Maze Therapeutics Trading Down 0.7%

Shares of MAZE stock traded down $0.26 during trading hours on Tuesday, reaching $38.37. 241,160 shares of the stock were exchanged, compared to its average volume of 330,787. The firm has a market capitalization of $1.85 billion and a price-to-earnings ratio of -1.84. Maze Therapeutics, Inc. has a 12-month low of $6.71 and a 12-month high of $43.29. The company’s 50-day moving average price is $37.15 and its 200-day moving average price is $25.26.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Wall Street Analysts Forecast Growth

Several brokerages have commented on MAZE. HC Wainwright upped their price objective on Maze Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, December 3rd. Guggenheim reissued a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Friday, December 19th. JPMorgan Chase & Co. raised their price target on shares of Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a research note on Monday, September 29th. Raymond James Financial initiated coverage on shares of Maze Therapeutics in a research report on Thursday, November 13th. They issued an “outperform” rating and a $48.00 price objective for the company. Finally, Wedbush upped their target price on shares of Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $43.38.

Institutional Trading of Maze Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Invesco Ltd. purchased a new stake in Maze Therapeutics in the first quarter worth about $226,000. Nuveen LLC bought a new stake in shares of Maze Therapeutics in the 1st quarter valued at about $125,000. Corebridge Financial Inc. purchased a new stake in shares of Maze Therapeutics in the 1st quarter worth approximately $48,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Maze Therapeutics in the 1st quarter worth approximately $57,000. Finally, Goldman Sachs Group Inc. bought a new position in shares of Maze Therapeutics during the first quarter valued at approximately $145,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.